In NEJM this week, a team of German researchers report a study of neoadjuvant chemotherapy combined with bevacizumab for the treatment of HER2-negative breast cancer. The team randomly assigned 1,948 patients to receive neoadjuvant epirubicin and cyclophosphamide followed by docetaxel, either with or without concomitant bevacizumab.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.